{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:29:13Z","timestamp":1784042953168,"version":"3.55.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["NRF-2021R1A2C2004224"],"award-info":[{"award-number":["NRF-2021R1A2C2004224"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by cartilage damage and bone erosion. Current pharmacological treatments often fail to repair damaged tissues and may cause severe immune-related side effects. Moreover, some patients exhibit inadequate responses to existing therapies. This study evaluated the therapeutic potential of extracellular vesicles (EV) derived from immortalized mesenchymal stem cells (iMSCs) overexpressing cytotoxic T lymphocyte-associated antigen-4 immunoglobulin fusion protein (CTLA4Ig) (CT-EV) compared with iMSC-derived EVs (ASC-EV).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Following EV characterization and in vitro functional assessments, collagen-induced arthritis (CIA) model mice (<jats:italic>n<\/jats:italic>\u2009=\u200910\/group) were treated with Dulbecco\u2019s phosphate-buffered saline (dPBS, 150 \u00b5L, twice weekly; Group C), ASC-EV (derived from the culture supernatant of 2\u2009\u00d7\u200910<jats:sup>6<\/jats:sup> iMSCs\/150 \u00b5L of dPBS, twice weekly; Group E), CT-EV (derived from the culture supernatant of 2\u2009\u00d7\u200910<jats:sup>6<\/jats:sup> CTLA4Ig-overexpressing iMSCs\/150 \u00b5L of dPBS, twice weekly; Group CT), or methotrexate (3\u00a0mg\/kg, three times per week; Group M). A normal control group received dPBS (150 \u00b5L, twice weekly; Group N).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>CT-EV showed a significant increase in EV quantity and the production of CTLA4, transforming growth factor \u03b21, and interleukin (IL)-1 receptor antagonist compared with ASC-EV. In mitogen-stimulated immune cells from CIA mice, CT-EV significantly reduced IL-6, IL-10, and Regulated upon Activation, Normal T cell Expressed and Presumably Secreted (RANTES) levels. Administration of both ASC-EV and CT-EV led to a decrease in macrophage proportions and an increase in T helper type 2 cells and serum IL-4 levels. Furthermore, CT-EV treatment resulted in additional reductions in anti-CII antibody levels, C-telopeptide II concentrations, and the proportion of CD138\u207a cells, thereby contributing to cartilage protection.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>CT-EV demonstrated superior therapeutic effects compared with ASC-EV in the CIA model, highlighting its potential as an effective treatment strategy for RA.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13287-025-04524-x","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:18:27Z","timestamp":1752538707000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Therapeutic effects of CTLA4Ig-overexpressing mesenchymal stem cell-derived extracellular vesicles in a mouse model of rheumatoid arthritis"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7213-695X","authenticated-orcid":false,"given":"Eun Wha","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Rang","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwoo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bongkum","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungjoo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"key":"4524_CR1","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s10787-018-0459-z","volume":"26","author":"MB Yu","year":"2018","unstructured":"Yu MB, Firek A, William HR, Langridge WHR. Predicting methotrexate resistance in rheumatoid arthritis patients. Inflammopharmacology. 2018;26:699\u2013708.","journal-title":"Inflammopharmacology"},{"key":"4524_CR2","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s10787-020-00741-3","volume":"28","author":"J Yu","year":"2020","unstructured":"Yu J, Zhou P. The advances of methotrexate resistance in rheumatoid arthritis. Inflammopharmacology. 2020;28:1183\u201393.","journal-title":"Inflammopharmacology"},{"key":"4524_CR3","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ejmech.2018.09.027","volume":"158","author":"W Wang","year":"2018","unstructured":"Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review. Eur J Med Chem. 2018;158:502\u201316.","journal-title":"Eur J Med Chem"},{"key":"4524_CR4","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1136\/ard.2006.065615","volume":"66","author":"GM Bartelds","year":"2007","unstructured":"Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BAC, Tak PP, Gerrit Jan Wolbink GJ. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66:921\u20136.","journal-title":"Ann Rheum Dis"},{"key":"4524_CR5","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1159\/000289205","volume":"11","author":"PP Sfikakis","year":"2010","unstructured":"Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun. 2010;11:180\u2013210.","journal-title":"Curr Dir Autoimmun"},{"key":"4524_CR6","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1056\/NEJMoa050524","volume":"353","author":"MC Genovese","year":"2005","unstructured":"Genovese MC, Becker J-C, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Dougados M. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor \u03b1 Inhibition. N Engl J Med. 2005;353:1114\u201323.","journal-title":"N Engl J Med"},{"key":"4524_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/1744666X.2019.1579642","volume":"15","author":"M Pombo-Suarez","year":"2019","unstructured":"Pombo-Suarez M, Gomez-Reino JJ. Abatacept for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2019;15:319\u201326.","journal-title":"Expert Rev Clin Immunol"},{"key":"4524_CR8","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s13287-023-03473-7","volume":"14","author":"M Babaahmadi","year":"2023","unstructured":"Babaahmadi M, Tayebi B, Gholipour NM, Kamardi MT, Heidari S, Baharvand H, Eslaminejad MB, Hajizadeh-Saffar E, Hassani S-N. Rheumatoid arthritis: the old issue, the new therapeutic approach. Stem Cell Res Ther. 2023;14:268.","journal-title":"Stem Cell Res Ther"},{"key":"4524_CR9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41584-020-00541-7","volume":"17","author":"MH Buch","year":"2021","unstructured":"Buch MH, Eyre S, McGonagle D. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol. 2021;17:17\u201333.","journal-title":"Nat Rev Rheumatol"},{"key":"4524_CR10","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s13287-024-03887-x","volume":"15","author":"MT Jouybari","year":"2024","unstructured":"Jouybari MT, Mojtahedi F, Babaahmadi M, Faeed M, Eslaminejad MB, Taghiyar L. Advancements in extracellular vesicle targeted therapies for rheumatoid arthritis: insights into cellular origins, current perspectives, and emerging challenges. Stem Cell Res Ther. 2024;15:276.","journal-title":"Stem Cell Res Ther"},{"key":"4524_CR11","doi-asserted-by":"publisher","first-page":"R210","DOI":"10.1186\/ar3187","volume":"12","author":"Y Liu","year":"2010","unstructured":"Liu Y, Mu R, Wang S, Long L, Liu X, Li R, Sun J, Guo J, Zhang X, Guo J, Yu P, Li C, Liu X, Huang Z, Wang D, Li H, Gu Z, Liu B, Li Z. Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res Ther. 2010;12:R210.","journal-title":"Arthritis Res Ther"},{"key":"4524_CR12","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1136\/ard.2008.101881","volume":"69","author":"E Gonzalez-Rey","year":"2010","unstructured":"Gonzalez-Rey E, Gonzalez MA, Varela N, O\u2019Valle F, Hernandez-Cortes P, Rico L, B\u00fcscher D, Delgado M. Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis. 2010;69:241\u20138.","journal-title":"Ann Rheum Dis"},{"key":"4524_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13287-022-02763-w","volume":"13","author":"R Vij","year":"2022","unstructured":"Vij R, Stebbings KA, Kim H, Park H, Chang D. Safety and efficacy of autologous, adipose-derived mesenchymal stem cells in patients with rheumatoid arthritis: a phase i\/iia, open-label, non-randomized pilot trial. Stem Cell Res Ther. 2022;13:88.","journal-title":"Stem Cell Res Ther"},{"key":"4524_CR14","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.7150\/thno.21072","volume":"8","author":"S Cosenza","year":"2018","unstructured":"Cosenza S, Toupet K, Maumus M, Luz-Crawford P, Blanc-Brude O, Jorgensen C, No\u00ebl D. Mesenchymal stem cells-derived exosomes are more immunosuppressive than microparticles in inflammatory arthritis. Theranostics. 2018;8:1399\u2013410.","journal-title":"Theranostics"},{"key":"4524_CR15","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.3390\/ijms15034142","volume":"15","author":"Y Bo","year":"2014","unstructured":"Bo Y, Xiaomin Z, Xiaorong L. Exosomes derived from mesenchymal stem. Int J Mol Sci. 2014;15:4142\u201357.","journal-title":"Int J Mol Sci"},{"key":"4524_CR16","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.4049\/jimmunol.1800304","volume":"201","author":"Z Chen","year":"2018","unstructured":"Chen Z, Wang H, Xia Y, Yan F, Lu Y. Therapeutic potential of mesenchymal Cell-Derived miRNA-150-5p-Expressing exosomes in rheumatoid arthritis mediated by the modulation of MMP14 and VEGF. J Immunol. 2018;201:2472\u201382.","journal-title":"J Immunol"},{"key":"4524_CR17","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12891-020-3159-y","volume":"21","author":"HY Meng","year":"2020","unstructured":"Meng HY, Chen LQ, Chen LH. The inhibition by human MSCs-derived miRNA-124a overexpression exosomes in the proliferation and migration of rheumatoid arthritis-related fibroblast-like synoviocyte cell. BMC Muscoskel Disord. 2020;21:150.","journal-title":"BMC Muscoskel Disord"},{"key":"4524_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13287-023-03295-7","volume":"14","author":"X Zhu","year":"2023","unstructured":"Zhu X, Ma D, Yang B, An Q, Zhao J, Gao X, Zhang L. Research progress of engineered mesenchymal stem cells and their derived exosomes and their application in autoimmune\/inflammatory diseases. Stem Cell Res Ther. 2023;14:71.","journal-title":"Stem Cell Res Ther"},{"key":"4524_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2492\/inflammregen.35.057","volume":"35","author":"K Ashiba","year":"2015","unstructured":"Ashiba K, Terunuma A, Terunuma H, Takane T, Deng X, Yamashita Y, Watanabe K. Immortalized mesenchymal stem cells producing conditioned medium in a large scale for therapeutic usage. Inflamm Regen. 2015;35:57\u201360.","journal-title":"Inflamm Regen"},{"key":"4524_CR20","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s13287-023-03523-0","volume":"4","author":"EW Choi","year":"2023","unstructured":"Choi EW, Lim IR, Park JH, Song J, Choi B, Kim S. Exosomes derived from mesenchymal stem cells primed with disease-condition-serum improved therapeutic efficacy in a mouse rheumatoid arthritis model via enhanced TGF-\u03b21 production. Stem Cell Res Ther. 2023;4:14:283.","journal-title":"Stem Cell Res Ther"},{"key":"4524_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jgm.1531","volume":"13","author":"EW Choi","year":"2011","unstructured":"Choi EW, Shin IS, Lee HW, Park SY, Park JH, Nam MH, Kim JS, Woo SK, Yoon EJ, Kang SK, Ra JC, Youn HY, Hong SH. Transplantation of CTLA4Ig gene-transduced adipose tissue-derived mesenchymal stem cells reduces inflammatory immune response and improves Th1\/Th2 balance in experimental autoimmune thyroiditis. J Gene Med. 2011;13:3\u201316.","journal-title":"J Gene Med"},{"key":"4524_CR22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3727\/096368915X688470","volume":"25","author":"EW Choi","year":"2016","unstructured":"Choi EW, Shin IS, Song JW, Lee M, Yun TW, Yang J, Choi KS, Kim SJ. Effects of transplantation of CTLA4Ig-overexpressing adipose tissue-derived mesenchymal stem cells in mice with sustained severe rheumatoid arthritis. Cell Transpl. 2016;25:243\u201359.","journal-title":"Cell Transpl"},{"key":"4524_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/art.33313","volume":"64","author":"EW Choi","year":"2012","unstructured":"Choi EW, Shin IS, Park SY, Park JH, Kim JS, Yoon EJ, Kang SK, Ra JC, Hong SH. Reversal of serologic, immunologic, and histologic dysfunction in mice with systemic lupus erythematosus by long-term serial adipose tissue-derived mesenchymal stem cell transplantation. Arthritis Rheum. 2012;64:243\u201353.","journal-title":"Arthritis Rheum"},{"key":"4524_CR24","doi-asserted-by":"publisher","first-page":"105687","DOI":"10.1016\/j.intimp.2019.105687","volume":"74","author":"D Ma","year":"2019","unstructured":"Ma D, Xu K, Zhang G, Liu Y, Gao J, Tian M, Wei C, Li J, Zhang L. Immunomodulatory effect of human umbilical cord mesenchymal stem cells on T lymphocytes in rheumatoid arthritis. Int Immunopharmacol. 2019;74:105687.","journal-title":"Int Immunopharmacol"},{"key":"4524_CR25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jcyt.2014.10.010","volume":"17","author":"EW Choi","year":"2015","unstructured":"Choi EW, Yun TW, Song JW, Lee M, Yang J, Choi KS. Preventive effects of CTLA4Ig-overexpressing adipose tissue-derived mesenchymal stromal cells in rheumatoid arthritis. Cytotherapy. 2015;17:271\u201382.","journal-title":"Cytotherapy"},{"key":"4524_CR26","doi-asserted-by":"publisher","first-page":"17297","DOI":"10.1038\/s41598-018-35602-1","volume":"8","author":"EW Choi","year":"2018","unstructured":"Choi EW, Song JW, Ha N, Choi YI, Kim S. CKD-506, a novel HDAC6-selective inhibitor, improves renal outcomes and survival in a mouse model of systemic lupus erythematosus. Sci Rep. 2018;8:17297.","journal-title":"Sci Rep"},{"key":"4524_CR27","doi-asserted-by":"publisher","first-page":"18532","DOI":"10.1038\/s41598-022-21381-3","volume":"12","author":"EW Choi","year":"2022","unstructured":"Choi EW, Kim HJ, Jung YC, Go HS, Seong JK. Effects of high fat diet-induced obesity on pathophysiology, immune cells, and therapeutic efficacy in systemic lupus erythematosus. Sci Rep. 2022;12:18532.","journal-title":"Sci Rep"},{"key":"4524_CR28","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1186\/s13287-020-01894-2","volume":"11","author":"F Liu","year":"2020","unstructured":"Liu F, Xie J, Zhang X, Wu Z, Zhang S, Xue M, Chen J, Yang Y, Qiu H. Overexpressing TGF-\u03b21 in mesenchymal stem cells attenuates organ dysfunction during CLP-induced septic mice by reducing macrophage-driven inflammation. Stem Cell Res Ther. 2020;11:378.","journal-title":"Stem Cell Res Ther"},{"key":"4524_CR29","first-page":"183","volume":"22","author":"MR Khorashad","year":"2023","unstructured":"Khorashad MR, Ghoryani M, Shabgah AG, Shariati-Sarabi Z, Afshari JT, Mohammadi M. The effects of mesenchymal stem cells on the gene expression of TGF-beta and IFN-gamma in patients with rheumatoid arthritis. Iran J Allergy Asthma Immunol. 2023;22:183\u20139.","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"4524_CR30","first-page":"203","volume":"6","author":"M Vohra","year":"2020","unstructured":"Vohra M, Sharma A, Bagga R, Arora SK. Human umbilical cord-derived mesenchymal stem cells induce tissue repair and regeneration in collagen-induced arthritis in rats. J Clin Transl Res. 2020;6:203\u201316.","journal-title":"J Clin Transl Res"},{"key":"4524_CR31","doi-asserted-by":"publisher","first-page":"e0193086","DOI":"10.1371\/journal.pone.0193086","volume":"13","author":"K Lee","year":"2018","unstructured":"Lee K, Park N, Jung H, Rim YA, Nam Y, Lee J, Park S-H, Ju JH. Mesenchymal stem cells ameliorate experimental arthritis via expression of interleukin-1 receptor antagonist. PLoS ONE. 2018;13:e0193086.","journal-title":"PLoS ONE"},{"key":"4524_CR32","first-page":"698313","volume":"2014","author":"Y Yosida","year":"2014","unstructured":"Yosida Y, Tanaka T. Interleukin 6 and rheumatoid arthritis. Biomed Res Int. 2014;2014:698313.","journal-title":"Biomed Res Int"},{"key":"4524_CR33","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1002\/eji.1830181122","volume":"18","author":"T Hirano","year":"1988","unstructured":"Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B, Sato K, Shimi M, Maid R, Feldmann M, Kishimoto T. Excessive production of interleukin 6\/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol. 1988;18:1797\u2013801.","journal-title":"Eur J Immunol"},{"key":"4524_CR34","doi-asserted-by":"publisher","first-page":"155742","DOI":"10.1016\/j.cyto.2021.155742","volume":"149","author":"M Jarlborg","year":"2022","unstructured":"Jarlborg M, Gabay C. Systemic effects of IL-6 blockade in rheumatoid arthritis beyond the joints. Cytokine. 2022;149:155742.","journal-title":"Cytokine"},{"key":"4524_CR35","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/1744666X.2017.1295850","volume":"13","author":"M Narazaki","year":"2017","unstructured":"Narazaki M, Tanaka T, Kishimoto T. The role and therapeutic targeting of IL-6 in rheumatoid arthritis. Expert Rev Clin Immunol. 2017;13:535\u201351.","journal-title":"Expert Rev Clin Immunol"},{"key":"4524_CR36","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.cyto.2017.02.022","volume":"95","author":"J Hern\u00e1ndez-Bello","year":"2017","unstructured":"Hern\u00e1ndez-Bello J, Oreg\u00f3n-Romero E, V\u00e1zquez-Villamar M, Garc\u00eda-Arellano S, Valle Y, Padilla-Guti\u00e9rrez JR, Rom\u00e1n-Fern\u00e1ndez IV, Palafox-S\u00e1nchez CA, Mart\u00ednez-Bonilla GE, Mu\u00f1oz-Valle JF. Aberrant expression of interleukin-10 in rheumatoid arthritis: relationship with IL10 haplotypes and autoantibodies. Cytokine. 2017;95:88\u201396.","journal-title":"Cytokine"},{"key":"4524_CR37","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/ar86","volume":"2","author":"RW Kinne","year":"2000","unstructured":"Kinne RW, Br\u00e4uer R, Stuhlm\u00fcller B, Palombo-Kinne E, Burmester G-R. Macrophages in rheumatoid arthritis. Arthritis Res. 2000;2:189\u2013202.","journal-title":"Arthritis Res"},{"key":"4524_CR38","doi-asserted-by":"publisher","first-page":"A68","DOI":"10.1136\/ard.2010.149013.3","volume":"70","author":"MJ Mart\u00ednez-Calatrava","year":"2011","unstructured":"Mart\u00ednez-Calatrava MJ, Zwerina J, Bragado R, Corb\u00ed AL, Largo R, Schett G, Herrero-Beaumont G. Effects of CTLA4-Ig on monocyte\/macrophage differentiation and cytokine production. Ann Rheum Dis. 2011;70:A68\u20139.","journal-title":"Ann Rheum Dis"},{"key":"4524_CR39","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1172\/JCI9244","volume":"106","author":"M Mihara","year":"2000","unstructured":"Mihara M, Tan I, Chuzhin Y, Reddy B, Budhai L, Holzer A, Gu Y, Davidson A. CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. J Clin Invest. 2000;106:91\u2013101.","journal-title":"J Clin Invest"},{"key":"4524_CR40","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.exphem.2009.01.005","volume":"37","author":"S Asari","year":"2009","unstructured":"Asari S, Itakura S, Ferreri K, Liu C-P, Kuroda Y, Kandeel F, Mullen Y. Mesenchymal stem cells suppress B-cell terminal differentiation. Exp Hematol. 2009;37:604\u201315.","journal-title":"Exp Hematol"},{"key":"4524_CR41","doi-asserted-by":"crossref","unstructured":"Pilat N, Mahr B, Gattringer M, Baranyi U, Wekerle T. CTLA4Ig improves murine iTreg induction via TGF \u03b2 and suppressor function in vitro. J Immunol Res. 2018;2484825.","DOI":"10.1155\/2018\/2484825"},{"key":"4524_CR42","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1074-7613(00)80195-8","volume":"12","author":"B Salomon","year":"2000","unstructured":"Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A, Bluestone JA. B7\/CD28 costimulation is essential for the homeostasis of the CD4\u2009+\u2009CD25\u2009+\u2009immunoregulatory T cells that control autoimmune diabetes. Immunity. 2000;12:431\u201340.","journal-title":"Immunity"},{"key":"4524_CR43","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1471-2172-14-34","volume":"14","author":"J Pieper","year":"2013","unstructured":"Pieper J, Herrath J, Raghavan S, Muhammad K, van Vollenhoven R. Malmstr\u00f6m V. CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunol. 2013;14:34.","journal-title":"BMC Immunol"},{"issue":"2\u20133","key":"4524_CR44","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s12026-014-8512-5","volume":"58","author":"L Pellerin","year":"2014","unstructured":"Pellerin L, Jenks JA, B\u00e9gin P, Bacchetta R, Nadeau KC. Regulatory T cells and their roles in immune dysregulation and allergy. Immunol Res. 2014;58(2\u20133):358\u201368.","journal-title":"Immunol Res"},{"issue":"2","key":"4524_CR45","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.berh.2015.05.009","volume":"29","author":"M Lahiri","year":"2015","unstructured":"Lahiri M, Dixon WG. Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis. Best Pract Res Clin Rheumat. 2015;29(2):290\u2013305.","journal-title":"Best Pract Res Clin Rheumat"},{"key":"4524_CR46","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1002\/acr2.11064","volume":"1","author":"G Ozen","year":"2019","unstructured":"Ozen G, Pedro S, England BR, Mehta B, Wolfe F, Michaud K. Risk of serious infection in patients with rheumatoid arthritis treated with biologic versus nonbiologic disease-modifying antirheumatic Srugs. ACR Open Rheumatol. 2019;1:424\u201332.","journal-title":"ACR Open Rheumatol"},{"key":"4524_CR47","doi-asserted-by":"publisher","first-page":"66834","DOI":"10.1186\/ar-2000-66834","volume":"3","author":"R Brasington","year":"2000","unstructured":"Brasington R. IL-4 gene therapy for collagen arthritis. Arthritis Res Ther. 2000;3:66834.","journal-title":"Arthritis Res Ther"},{"key":"4524_CR48","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/glia.20841","volume":"57","author":"L Bai","year":"2009","unstructured":"Bai L, Lennon DP, Eaton V, Maier K, Caplan AI, Miller SD, Miller RH. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia. 2009;57:1192\u2013203.","journal-title":"Glia"},{"key":"4524_CR49","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1186\/s13287-024-03947-2","volume":"15","author":"M Mendiratta","year":"2024","unstructured":"Mendiratta M, Mendiratta M, Ganguly S, Rai S, Gupta R, Kumar L, Bakhshi S, Dadhwal V, Pushpam D, Malik PS, Pramanik R, Aggarwal M, Gupta AK, Dhawan R, Seth T, Mahapatra M, Nayak B, Singh TD, Kumar S, Mir RA, Kaur G, GuruRao H, Singh M, Prasad CP, Prakash H, Mohanty S, Sahoo RK. Concurrent hypoxia and apoptosis imparts immune programming potential in mesenchymal stem cells: lesson from acute graft-versus-host-disease model. Stem Cell Res Ther. 2024;15:381.","journal-title":"Stem Cell Res Ther"},{"key":"4524_CR50","doi-asserted-by":"publisher","first-page":"209e15","DOI":"10.1016\/S8756-3282(01)00504-X","volume":"29","author":"S Christgau","year":"2001","unstructured":"Christgau S, Garnero P, Fledelius C, Moniz C, Ensig M, Gineyts E, Rosenquist C, Qvist C. Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone. 2001;29:209e15.","journal-title":"Bone"},{"key":"4524_CR51","doi-asserted-by":"crossref","unstructured":"Silva JD, de Castro LL, Braga CL, Oliveira GP, Trivelin SA, Barbosa-Junior CM, Morales MM, dos Santos CC, Weiss DJ, Lopes-Pacheco M, Cruz FF, Rocco PRM. Mesenchymal stromal cells are more effective than their extracellular vesicles at reducing lung injury regardless of acute respiratory distress syndrome etiology. Stem Cells Int. 2019;8262849.","DOI":"10.1155\/2019\/8262849"},{"key":"4524_CR52","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1186\/s12951-022-01728-8","volume":"20","author":"J Kim","year":"2022","unstructured":"Kim J, Lee SK, Jung M, Jeong SY, You H, Won JY, Han SD, Cho HJ, Park S, Park J, Kim TM, Kim S. Extracellular vesicles from IFN-\u03b3-primed mesenchymal stem cells repress atopic dermatitis in mice. J Nanobiotechnol. 2022;20:526.","journal-title":"J Nanobiotechnol"},{"key":"4524_CR53","doi-asserted-by":"publisher","first-page":"1265291","DOI":"10.1080\/20013078.2017.1265291","volume":"6","author":"ZQ Yuan","year":"2017","unstructured":"Yuan ZQ, Kolluri KK, Gowers KHC, Janes SM. TRAIL delivery by MSC-derived extracellular vesicles is an effective anticancer therapy. J Extracell Vesicles. 2017;6:1265291.","journal-title":"J Extracell Vesicles"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04524-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-025-04524-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-025-04524-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T10:56:24Z","timestamp":1757242584000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-025-04524-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4524"],"URL":"https:\/\/doi.org\/10.1186\/s13287-025-04524-x","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"10 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed and approved by the IACUC of Kangwon National University (KW-210824-1) and the IACUC of GenNBio (GN-IACUC-22-01-10) as follows; for in vitro functional test: (1) Title of the approved project: The effects of advanced mesenchymal stem cell-derived materials on rheumatoid arthritis (2) Name of the institutional approval committee: IACUC of Kangwon National University (3) Approval number: KW-210824-1 (4) Date of approval: August 30, 2021 \/ for in vivo study: (1) Title of the approved project: The therapeutic effect of advanced exosome in mouse rheumatoid arthritis model (2) Name of the institutional approval committee: IACUC of GenNBio (3) Approval number: GN-IACUC-22-01-10 (4) Date of approval: January 14, 2022.We received review exemptions from the Institutional Review Board (IRB) for the use of anonymized human iMSCs (ATCC, Manassas, Virginia) and CTLA4Ig-overexpressing iMSCs (CTLA4Ig-iMSCs) (KWNUIRB-2021-04-009-001) as follows; (1) Title of the approved project: Development of next-generation therapeutic agents for autoimmune diseases using advanced mesenchymal stem cell-derived materials (2) Name of the institutional approval committee: IRB of Kangwon National University (3) Approval number: KWNUIRB-2021-04-009-001 (4) Date of approval: May 17, 2021.Human iMSCs were purchased from a commercial vendor (ATCC). ATCC has confirmed that there was initial ethical approval for collection of human cells, and that the donors had signed informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JS, BC, and SK are employees of GenNBio Inc. The remaining authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"374"}}